New Tumor Drugs Targets Solutions

A tumor refers to an abnormal lesion formed by a clonal abnormal proliferation of a certain cell in a local tissue under the action of various carcinogenic factors, which loses normal growth regulation at the gene level. In academia, tumors are generally divided into two categories: benign tumors and malignant tumors.

Through TCGA big data, we analyzed the high expression or expression of genes related to disease staging and classification in cancer tissues and genes related to survival, and analyzed candidate genes through our database of key disease genes. Using the lentivirus-mediated RNAi technology, through the Cellomics High Content Functional Screening (HCS) platform, several candidate genes are RNAi, and the infected cells are counted for 4 to 5 days. Genes affecting cell proliferation were discovered. Positive results from at least three proliferative function experiments and two metastatic function experiments obtained two interference targets of a gene on a cell line. The change of cell proliferation ability was observed by HCS scanning for 5 days to verify the function of the downstream mechanism genes to restore the function of the target genes. Positive results from proliferation- and metastasis-related functional experiments were obtained.

New Tumor Drugs Targets Solutions

Search for Downstream Mechanisms of Target Molecules / Drugs

Our Advantage

Mature and reliable Search for New Tumor Drugs Targets Solutions platform: rich project experience, participate in major projects, and publish high-level cooperation results.

The analysis contents and methods based on high-quality data analysis, pre-research and verification are indeed mature and feasible.

Please contact us to find out how we can help you achieve the next research breakthrough.

Learn More

* For Research Use Only. Not for use in the treatment or diagnosis of disease.

Related Services:

CONTACT US

  • USA
  • Tel:
  • Fax:
  • Email:
  • Germany

GET IN TOUCH

Copyright © 2024 Creative Proteomics. All rights reserved.